These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 25035353)

  • 1. Intermediate doses of rituximab used as adjuvant therapy in refractory pemphigus.
    Londhe PJ; Kalyanpad Y; Khopkar US
    Indian J Dermatol Venereol Leprol; 2014; 80(4):300-5. PubMed ID: 25035353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single cycle of rituximab for the treatment of severe pemphigus.
    Joly P; Mouquet H; Roujeau JC; D'Incan M; Gilbert D; Jacquot S; Gougeon ML; Bedane C; Muller R; Dreno B; Doutre MS; Delaporte E; Pauwels C; Franck N; Caux F; Picard C; Tancrede-Bohin E; Bernard P; Tron F; Hertl M; Musette P
    N Engl J Med; 2007 Aug; 357(6):545-52. PubMed ID: 17687130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.
    Cianchini G; Lupi F; Masini C; Corona R; Puddu P; De Pità O
    J Am Acad Dermatol; 2012 Oct; 67(4):617-22. PubMed ID: 22243765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose rituximab as an adjuvant therapy in pemphigus.
    Gupta J; Raval RC; Shah AN; Solanki RB; Patel DD; Shah KB; Badheka AD; Shah KB; Aggarwal NK; Ravishankar V
    Indian J Dermatol Venereol Leprol; 2017; 83(3):317-325. PubMed ID: 28366912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities.
    Cho HH; Jin SP; Chung JH
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):186-91. PubMed ID: 23356542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line treatment of pemphigus vulgaris with a combination of rituximab and high-potency topical corticosteroids.
    Ingen-Housz-Oro S; Valeyrie-Allanore L; Cosnes A; Ortonne N; Hüe S; Paul M; Wolkenstein P; Chosidow O
    JAMA Dermatol; 2015 Feb; 151(2):200-3. PubMed ID: 25354242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab treatment of severe pemphigus: long-term results including immunologic follow-up.
    Reguiai Z; Tabary T; Maizières M; Bernard P
    J Am Acad Dermatol; 2012 Oct; 67(4):623-9. PubMed ID: 22261417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful use of rituximab in the treatment of childhood and juvenile pemphigus.
    Vinay K; Kanwar AJ; Sawatkar GU; Dogra S; Ishii N; Hashimoto T
    J Am Acad Dermatol; 2014 Oct; 71(4):669-75. PubMed ID: 25022850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose rituximab is effective in pemphigus.
    Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF
    Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study.
    Sharma VK; Bhari N; Gupta S; Sahni K; Khanna N; Ramam M; Sethuraman G
    Indian J Dermatol Venereol Leprol; 2016; 82(4):389-94. PubMed ID: 27279296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intralesional Rituximab in the Treatment of Refractory Oral Pemphigus Vulgaris.
    Vinay K; Kanwar AJ; Mittal A; Dogra S; Minz RW; Hashimoto T
    JAMA Dermatol; 2015 Aug; 151(8):878-82. PubMed ID: 25536513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durable remission of pemphigus with a fixed-dose rituximab protocol.
    Heelan K; Al-Mohammedi F; Smith MJ; Knowles S; Lansang P; Walsh S; Shear NH
    JAMA Dermatol; 2014 Jul; 150(7):703-8. PubMed ID: 24500264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of severe pemphigus with protein A immunoadsorption, rituximab and intravenous immunoglobulins.
    Shimanovich I; Nitschke M; Rose C; Grabbe J; Zillikens D
    Br J Dermatol; 2008 Feb; 158(2):382-8. PubMed ID: 18070210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.
    Faurschou A; Gniadecki R
    Int J Dermatol; 2008 Mar; 47(3):292-4. PubMed ID: 18289336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged treatment with rituximab in patients with refractory pemphigus vulgaris.
    Barrera MV; Mendiola MV; Bosch RJ; Herrera E
    J Dermatolog Treat; 2007; 18(5):312-4. PubMed ID: 17852643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of 19 patients with severe pemphigus: prophylactic treatment with rituximab does not appear to be beneficial.
    Gregoriou S; Giatrakou S; Theodoropoulos K; Katoulis A; Loumou P; Toumbis-Ioannou E; Papadavid E; Avgerinou G; Stavrianeas N; Rigopoulos D
    Dermatology; 2014; 228(2):158-65. PubMed ID: 24557145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature.
    Cianchini G; Corona R; Frezzolini A; Ruffelli M; Didona B; Puddu P
    Arch Dermatol; 2007 Aug; 143(8):1033-8. PubMed ID: 17709662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab).
    Marzano AV; Fanoni D; Venegoni L; Berti E; Caputo R
    Dermatology; 2007; 214(4):310-8. PubMed ID: 17460402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of rituximab treatment in Indian pemphigus patients.
    Kanwar AJ; Tsuruta D; Vinay K; Koga H; Ishii N; Dainichi T; Hashimoto T
    J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e17-23. PubMed ID: 22176540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations.
    Craythorne E; du Viver A; Mufti GJ; Warnakulasuriya S
    J Oral Pathol Med; 2011 Sep; 40(8):616-20. PubMed ID: 21385212
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.